Abstract 4191: The worldwide female breast cancer incidence and survival, 2018
Notice bibliographique
Résumé
Abstract Background: this communication presents the latest international descriptive epidemiological data for invasive breast cancer amongst women, including incidence and survival in the worldwide. Methods: the incidence statistics presented here for cancers worldwide were taken from the International Agency for Research on Cancer IARC: * The Cancer Incidence in five Continents Vol XI.* GLOBOCAN 2018. *The datas of Cancer survival are taken from: * Cancer survival in five continents, a worldwide population-based study or Concord Study Version 1, 2 and 3. These Concord studies included 101 population-based cancer registries in 31 countries for the period 1990-1994 and followed up to 1999 for the Concord Study 1, 279 population-based cancer registries in 67 countries for the period 1995-2009 for the Concord Study 2 and 412 cancer registries in 85 countries for the period 2000-14 for the Concord Study 3 Results: breast cancer is by far the most frequent cancer among women with an estimated. 2 million new cancer cases diagnosed in 2018 (23% of all cancers), and ranks second overall (10.9% of all cancers). It is now the most common cancer both in developed and developing regions.* Incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women in Western Europe, and are high (greater than 80 per 100,000) in developed regions of the world (except Japan) and low (less than 40 per 100,000) in most of the developing regions.For women diagnosed during 2010-14, the range of survival estimates is still wide in each continent, apart from North America and Oceania with 5-year net survival approached 90%. **Age-standardised 5-year net survival was 85% or higher in 25 countries, Costa Rica, Martinique, Canada and the USA, Israel, Japan and 16 European countries, Denmark, Finland, Iceland, Norway, Sweden, UK, Austria, Belgium, France, Germany, the Netherlands, and Switzerland and Italy, Malta, Portugal and Spain. **5-year survival was in the range 80-84% in 12 countries, three countries in Central and South America Argentina, Peru, and Puerto Rico, five Asian countries (Singapore, China, Hong Kong and Taiwan and Turkey and four European countries the Czech Republic and Latvia and Slovenia.**Survival was in the range 70-79% in 12 countrie, Cuba and Ecuador, Kuwait and Mongolia and eight countries in Europe, Estonia, Lithuania, Croatia and Bulgaria and Poland. **Breast cancer survival remains lower in Eastern Europe and Africa. Conclusion: the future worldwide breast cancer burden will be strongly influenced by large predicted rises in incidence throughout parts of Asia due to an increasingly westernised lifestyle. Efforts are underway to reduce the global disparities in survival for women with breast cancer using cost-effective interventions. Note: This abstract was not presented at the meeting. Citation Format: Zoubida Zaidi, Hussain Adlane Dib. The worldwide female breast cancer incidence and survival, 2018 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4191.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».